-The Pioneer While the Government has done its bit to boost the output of pulses, it has done little to check the nexus between politicians and grain traders For several decades, production of pulses in India has fallen substantially short in terms of consumption. This persistent deficit has led to intermittent bouts of spike in prices as imports (needed to plug it) have often come after lag and have failed to reach...

-Frontline Low prices following a bumper crop and the State government’s inability to procure much of the yield leave tur farmers in Maharashtra in a quandary. DROUGHT or abundance, farmers seem to be perpetually doomed in Maharashtra. The most recent crisis unfolding in the agrarian segment is the crashing prices of pulses, particularly tur dal, and the inability of the State government to procure the entire crop. Adding to the problem...

-Business Standard Till date, government has procured over 27 million tonnes of wheat By all estimates, wheat procurement is expected to be around 30 million tonnes in 2017-18, short of the initial target of 33 million tonnes.   Food Minister Ramvilas Paswan in an interview to Business Standard did estimate that final procurement figures could be around 30 million tonnes, but said that it won't have any impact on stocks as the purchases were...

-The Financial Express Thanks to normal monsoon rains last year after two consecutive years of ‘deficient’ rainfall, India’s foodgrain production is estimated to touch an all-time high of 273.38 million tonne (MT) in the 2016-17 crop year (July-June), which is 8.7% more than the previous year. The previous record output was 265.04 MT in 2013-14. According to the third advance estimate released on Tuesday by agriculture ministry, the output of rice, wheat,...

-The Telegraph New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries. It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer. The pre-qualification process is a mechanism...